Topic Name

Message

If ARUP Consult does not answer your test selection and interpretation questions, or if you would like to suggest ways to improve content or usability, please send a message to the Consult editorial staff.

Please do not include any patient-specific or personal health information (PHI) in your message.

Email Address

An email address is not required, but providing one allows the ARUP Consult editorial staff to respond directly. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use.

CAPTCHA

What code is in the image?

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Genotype-Guided Antidepressant Selection

Pharmacogenetics Panel: Psychotropics 3004471

3001524

Cytochrome P450 Genotyping Panel 3001524

3004255

Cytochrome P450 Genotyping Panel, with GeneDose Access 3004255

About This Topic

For patients with depression, use of CYP2D6 and CYP2C19 genotypes to select drugs and dosages may reduce the time to therapeutic success.

Recommendation

Guide antidepressant drug selection by CYP2D6 (3001513) and CYP2C19 (3001508) genotype to reduce the time to successful therapeutic depression treatment.

Other genotyping panels that include these gene targets are the Pharmacogenetics Panel: Psychotropics (3004471), Cytochrome P450 Genotyping Panel (3001524), and Cytochrome P450 Genotyping Panel, with GeneDose Live Access (3004255).

ARUP Consult

CPIC Guideline for Tricyclic Antidepressants

Clinical Pharmacogenetics Implementation Consortium. CPIC guideline for tricyclic antidepressants and CYP2D6 and CYP2C19. Updated Oct 2019; accessed Jul 2022.

Feedback

Genotype-Guided Antidepressant Selection

CPIC Guideline for Tricyclic Antidepressants